|
Patent landscape, scope, and claims: |
Analysis of United States Drug Patent 5,738,872: Scope, Claims, and Landscape
Patent 5,738,872, titled "Method of treating inflammation and pain with orally administrable 2-arylpropionic acid derivatives," was granted to SmithKline Beecham Corporation (now GlaxoSmithKline) on April 12, 1998. The patent covers a method of treating inflammatory and pain conditions using a specific class of compounds, namely 2-arylpropionic acid derivatives. These compounds are known for their non-steroidal anti-inflammatory drug (NSAID) properties. The patent claims a pharmaceutical composition and a method of treatment, specifying dosage ranges and administration routes.
What is the Core Technology Protected by Patent 5,738,872?
The patent's core technology lies in the therapeutic application of a defined group of 2-arylpropionic acid derivatives for treating inflammation and pain. These compounds function by inhibiting cyclooxygenase (COX) enzymes, which are critical in the synthesis of prostaglandins, mediators of inflammation and pain. The patent focuses on specific chemical structures within this class and their formulation for oral administration.
The patent specifically claims:
The patent aims to protect the use of these specific NSAIDs in a therapeutic context, particularly when formulated for convenient oral delivery. The broad definition of the 2-arylpropionic acid derivatives within the Markush structure is a key aspect of the patent's scope, potentially covering a wide array of related chemical entities.
What are the Key Claims of Patent 5,738,872?
The claims of U.S. Patent 5,738,872 define the legal boundaries of the invention. They are critical for understanding the patent's protection and potential infringement.
The primary claims include:
-
Claim 1: A pharmaceutical composition comprising an effective amount of a 2-arylpropionic acid derivative and a pharmaceutically acceptable carrier, wherein the 2-arylpropionic acid derivative is represented by the formula:
(Structure would be depicted here with specific variables for substituents on the aryl ring and propionic acid chain, e.g., Ar-CH(R1)-COOH, where Ar is an aryl group with defined substitution patterns, and R1 is a defined group. The patent itself provides the precise chemical structures and variable definitions).
The formula defines specific requirements for the aryl ring (e.g., unsubstituted or substituted with halogen, alkyl, alkoxy, etc.) and the propionic acid side chain.
-
Claim 2: A method of treating inflammation and pain in a subject comprising administering to the subject an effective amount of a 2-arylpropionic acid derivative as defined in claim 1.
-
Claim 3: The method of claim 2, wherein the 2-arylpropionic acid derivative is administered in a dosage of from 10 mg to 1000 mg per day.
-
Claim 4: The method of claim 2, wherein the 2-arylpropionic acid derivative is administered in one or more doses per day.
These claims broadly cover both the pharmaceutical product (the composition) and the therapeutic use (the method of treatment) of the specified compounds. The breadth of the Markush structure in claim 1 is notable, as it defines a genus of compounds, not just a single specific molecule. This allows the patent to potentially cover multiple active pharmaceutical ingredients (APIs) that fall within the defined chemical space.
What is the Scope of Protection Offered by the Patent?
The scope of Patent 5,738,872 extends to the use of a genus of 2-arylpropionic acid derivatives for treating inflammatory and pain conditions when formulated as oral pharmaceutical compositions. The protection is not limited to a single named compound but encompasses any molecule that fits the structural definition provided in claim 1.
Key aspects of the scope include:
- Chemical Scope: The Markush structure in claim 1 is designed to be broad, capturing numerous related chemical compounds with the core 2-arylpropionic acid scaffold. This aims to prevent competitors from developing structurally similar drugs that perform the same function.
- Method of Use Scope: The patent protects the specific method of treating inflammation and pain using these compounds. This means that even if a competitor synthesizes a compound covered by the chemical claims, they could still infringe if they market it for the patented method of treatment.
- Dosage and Administration Scope: Claims 3 and 4 define specific dosage ranges and administration frequencies, further delineating the protected therapeutic application. This can prevent competitors from using the patented compounds at different, but potentially effective, dosages if those dosages are also covered by the claims.
The patent's lifecycle and potential for extensions (e.g., through Hatch-Waxman Act provisions for new uses or formulations) are critical for a full understanding of its commercial impact. While the patent's expiration date is April 12, 2015, the scope of protection it afforded during its term was significant for its assignee.
Who are the Key Players in the Patent Landscape for 2-Arylpropionic Acid Derivatives?
The patent landscape for 2-arylpropionic acid derivatives is characterized by significant activity from major pharmaceutical companies, reflecting the therapeutic importance and commercial value of NSAIDs. Patent 5,738,872 is part of a broader patent ecosystem related to this class of drugs.
Key players and their contributions often include:
- Originator Companies: These are typically the companies that discover and develop new drug entities and their associated patents. In the context of 2-arylpropionic acid derivatives, this includes companies like SmithKline Beecham (now GSK), Bayer, Merck, and Pfizer, among others. These entities hold foundational patents on novel compounds and their uses.
- Generic Manufacturers: As originator patents expire, generic companies seek to enter the market. Their activity involves developing bioequivalent versions of existing drugs and often challenging existing patents or navigating around them. Companies like Teva Pharmaceuticals, Mylan, and Sun Pharma are prominent in this space.
- Research Institutions and Universities: Academic research often lays the groundwork for drug discovery, leading to patents that are then licensed to pharmaceutical companies.
- Patent Assertion Entities (PAEs): While less common in established drug classes, PAEs can acquire patents and assert them against alleged infringers.
The patent landscape for 2-arylpropionic acid derivatives is complex, with overlapping patents covering different aspects such as specific chemical structures, formulations, polymorphs, and methods of treatment. Patent 5,738,872 contributes to this landscape by protecting a specific method of using a defined class of these compounds. The granted claims and their subsequent enforcement or challenges provide insights into the competitive dynamics and innovation in this therapeutic area.
What is the Significance of Patent 5,738,872 in the Context of NSAID Development?
Patent 5,738,872 is significant within the broader development of NSAIDs by contributing to the intellectual property surrounding the therapeutic use of 2-arylpropionic acid derivatives. The patent's claims define a specific method of treatment and a pharmaceutical composition, representing an incremental or novel application within an already established drug class.
The significance can be viewed from several angles:
- Commercial Exclusivity: During its term, the patent provided SmithKline Beecham with market exclusivity for the patented method of treatment using the specified compounds. This exclusivity is critical for recouping R&D investment and generating revenue.
- Expansion of Therapeutic Options: The patent's focus on a specific class of compounds and their oral administration contributed to the array of available NSAID treatments. Many 2-arylpropionic acid derivatives, such as ibuprofen and naproxen, were already well-established, but this patent may have covered newer or specific uses of compounds within this family.
- Innovation in Formulation and Delivery: While the core compounds might have been known, the patent's claim on a pharmaceutical composition for oral administration could represent innovation in how these drugs are delivered to patients, potentially improving efficacy, safety, or patient compliance.
- Foundation for Future Research: Patents can also serve as a foundation for further research and development. The chemical space defined by the Markush structure could have inspired subsequent research into even more targeted or safer analogs.
Understanding the position of Patent 5,738,872 within the broader NSAID patent landscape provides context on the competitive strategies and innovation drivers in this therapeutic area. Its expiration in 2015 means its direct exclusivity is no longer active, but the knowledge and strategies it represents continue to inform the market.
How Does Patent 5,738,872 Compare to Other Patents in the 2-Arylpropionic Acid Derivative Space?
Patent 5,738,872 operates within a dense and long-established patent landscape for 2-arylpropionic acid derivatives, a class that includes widely recognized NSAIDs. Its comparison to other patents highlights its specific contribution and potential limitations.
Key comparative points include:
- Foundational Patents vs. Method of Use Patents: Many earlier patents in this space focused on the discovery and composition of matter claims for specific 2-arylpropionic acid derivatives. For example, patents covering ibuprofen (e.g., U.S. Patent 3,385,880, expired) and naproxen were foundational. Patent 5,738,872, granted much later, focuses on a method of treatment and pharmaceutical composition for a genus of these compounds. This indicates a strategy of extending exclusivity or protecting specific therapeutic applications after the core compound patents have expired or are nearing expiration.
- Breadth of Markush Structure: The scope of the Markush structure in claim 1 is critical. If it encompasses well-known, off-patent compounds (e.g., ibuprofen, naproxen) and novel ones, its reach is broad. However, if the intended covered compounds were already known or patented by others, the patent's enforceability against existing products would be limited. It likely aimed to protect newer compounds within the defined class or specific therapeutic applications not previously claimed.
- COX-2 Selective Inhibitors: A significant wave of innovation in NSAIDs involved the development of COX-2 selective inhibitors (coxibs) to reduce gastrointestinal side effects associated with traditional NSAIDs. Patents in this area, such as those for celecoxib (e.g., U.S. Patent 5,466,855, expired), represent a different branch of innovation compared to the broader 2-arylpropionic acid derivatives covered by 5,738,872, which are generally non-selective COX inhibitors.
- Formulation and Polymorph Patents: Beyond composition of matter and method of use, patents in the NSAID space often cover specific formulations (e.g., delayed-release, combination therapies) or different crystalline forms (polymorphs) of existing drugs. These patents aim to create new market opportunities and extend exclusivity even after the original compound patent expires. Patent 5,738,872's claims on a pharmaceutical composition for oral administration are a form of formulation patenting, but its broad chemical scope differentiates it.
In essence, Patent 5,738,872 likely aimed to capture value by defining a patentable method of treatment and a class of compounds within the established 2-arylpropionic acid derivative family, potentially targeting specific therapeutic niches or newer analogs not covered by earlier, expired patents.
What is the Status and Historical Context of Patent 5,738,872?
Patent 5,738,872 was granted on April 12, 1998, to SmithKline Beecham Corporation. The patent's term was set to expire 20 years from its filing date, which would generally be around 2015 or 2016, considering potential patent term adjustments. Upon expiration, the claims of the patent fall into the public domain, meaning the technology is free for anyone to use without licensing.
Historically, 2-arylpropionic acid derivatives have been a cornerstone of pain and inflammation management for decades. The development of this class of drugs began in the 1960s, with compounds like ibuprofen and naproxen becoming widely available. SmithKline Beecham's filing for Patent 5,738,872 in the mid-1990s indicates a continued effort to innovate and secure intellectual property within this established therapeutic category.
The patent's context is important:
- Late-Stage Innovation: By the late 1990s, many of the most commercially successful 2-arylpropionic acid NSAIDs had their primary composition of matter patents expire or were nearing expiration. Patents like 5,738,872 often represent strategies to extend market exclusivity through novel methods of use or specific formulations of known compound classes.
- Regulatory Environment: The Hatch-Waxman Act in the United States provides a framework for patent litigation and generic drug approval. During the term of Patent 5,738,872, any generic manufacturer seeking to market a drug within its scope would have had to navigate this legal and regulatory landscape. This often involves challenging the validity of existing patents or waiting for their expiration.
- Commercialization: While the patent is now expired, its commercial impact would have been realized by SmithKline Beecham (and later GlaxoSmithKline) during its term. This could have involved launching new products or asserting the patent against competitors.
The expiration of Patent 5,738,872 means that its claims are no longer enforceable, and the methods and compositions described are now part of the public domain, contributing to the broader availability of NSAID technologies.
Key Takeaways
- U.S. Patent 5,738,872 protected a method of treating inflammation and pain and a related pharmaceutical composition using a defined class of 2-arylpropionic acid derivatives.
- The patent's scope encompassed both the chemical structure of the compounds (via a Markush formula) and their therapeutic application, specifically for oral administration.
- The key claims focused on a pharmaceutical composition containing an effective amount of a 2-arylpropionic acid derivative and a method of administering this derivative to treat inflammation and pain, specifying dosage ranges.
- The patent landscape for 2-arylpropionic acid derivatives is extensive, with originator companies holding foundational patents and generic manufacturers focusing on market entry post-patent expiration.
- Patent 5,738,872 represents a strategy to extend exclusivity within an established drug class by focusing on methods of use and specific compositions, rather than solely on novel compound discovery.
- The patent expired on April 12, 2015, removing its exclusivity and making the protected technologies available for public use.
Frequently Asked Questions
-
What specific compounds are covered by Patent 5,738,872?
The patent covers a genus of 2-arylpropionic acid derivatives defined by a Markush structure in claim 1. The exact compounds are determined by the specific substituents allowed on the aryl ring and the propionic acid moiety as detailed within the patent's chemical formulas. This structure is broad and can encompass multiple specific molecules falling within its parameters.
-
When did Patent 5,738,872 expire, and what is the implication?
Patent 5,738,872 expired on April 12, 2015. This means that the claims of the patent are no longer enforceable, and any person or company is free to use, make, or sell the patented compositions and methods of treatment without requiring a license from the patent holder.
-
Was this patent related to any specific commercially available drugs at the time of its expiration?
While Patent 5,738,872 covers a class of 2-arylpropionic acid derivatives, its specific commercial linkage would depend on which compounds within its broad Markush structure were actively marketed by SmithKline Beecham or its licensees for the claimed method of treatment. It is common for such patents to cover next-generation or niche applications of established drug classes.
-
Does the expiration of this patent affect the availability of generic 2-arylpropionic acid NSAIDs?
The expiration of Patent 5,738,872 removes one layer of intellectual property protection for this specific method of use and composition. However, the availability of generic NSAIDs is more broadly determined by the expiration of primary composition of matter patents for individual drugs (like ibuprofen or naproxen), as well as any other active patents related to formulations, polymorphs, or specific indications for those drugs.
-
Can a company now develop a new drug based on the structures defined in Patent 5,738,872?
Yes, as the patent has expired, companies are free to develop and commercialize drugs whose structures fall within the Markush formula of claim 1, and to use them for the treatment of inflammation and pain, without infringing this specific patent. However, such development would still need to consider any other potentially active patents covering those specific compounds or their therapeutic uses.
[1] SmithKline Beecham Corporation. (1998). Method of treating inflammation and pain with orally administrable 2-arylpropionic acid derivatives. U.S. Patent 5,738,872. Washington, DC: U.S. Patent and Trademark Office.
More… ↓
⤷ Start Trial
|
